Title: Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617
Authors: SATHEKGE MIKEBRUCHERTSEIFER FRANKLAWAL IVORSTER MARIZAKNOESEN OTTOLENGANA TBOSHOMANE TMOKOALA KMORGENSTERN ALFRED
Citation: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 46 no. 8 p. 1756-1757
Publisher: SPRINGER
Publication Year: 2019
JRC N°: JRC116617
ISSN: 1619-7070 (online)
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC116617
DOI: 10.1007/s00259-019-04354-z
Type: Articles in periodicals and books
Abstract: Brain metastases are not common in prostate cancer; they typically occur in patients with end-stage disease who are castrate-resistant. Patients with brain metastases have very limited survival. Traditionally, the mainstays of therapy have been surgical resection, chemotherapy and external beam radiotherapy. Recently, combination of 177Lu-Prostatespecific membrane antigen (PSMA)-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer (mCRPC) showed significant regression in the sizes and PSMA-ligand avidity of the lesions over time. Recent studies have demonstrated that targeted α-radiation therapy with 225Ac-PSMAligand can significantly benefit patients with mCRPC in the appropriate setting. Targeted α-radiation therapy may be more effective for the treatment of mCRPC, and has been shown, in limited number of patients, to be effective in the setting of resistant to 177Lu-PSMA-617 therapy.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.